"If it’s not a chemical imbalance, then what do I have?” An updated account of depression for both patients and practitioners

This presentation will summarize recent findings on the neurobiology of depression, and distill these findings into a narrative form that is more clearly comprehensible to practitioners and patients alike. Updated explanatory models of depression may help patients better understand their own illness, make sense of the symptoms they experience, and make better informed choices about which treatment options to pursue, as neuromodulation treatments enter increasingly widespread use in the community.

"If it’s not a chemical imbalance, then what do I have?”  An updated account of depression for both patients and practitioners.

You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: If it’s not a chemical imbalance, then what do I have?”  An updated account of depression for both patients and practitioners, featuring Jonathan Downar, MD, PhD, FRCPC! 

Don't miss out on our Q&A portion of the webinar!

At the end of this presentation, participants will be able to: 

1. To review recent advances in our understanding of the neurobiology of depression.

2. To understand how these advances shed light on the mechanisms of old and new treatments for depression.

3. To acquire more accurate and more comprehensible updated narratives for explaining depression and its treatment to patients and members of the lay public

Date: December 6, 2022 at 5 pm PST, 7 pm CST, 8 pm EST

Format: Live Via Zoom

Cost: Members: $25 | Non-members $50 | Student Members FREE


Jonathan Downar, MD, PhD, FRCPC

Dr Jonathan Downar is an Associate Professor in Psychiatry and a Senior Fellow at Massey College at the University of Toronto.  His work over the last 25 years has spanned the translational spectrum from basic science work using functional neuroimaging to randomized controlled trials of novel treatment protocols for transcranial magnetic stimulation.  He is the senior author of the widely cited THREE-D study, published in Lancet in 2018, that led to formal FDA approval for 3 minute theta-burst TMS in depression.  He enjoys close collaborations with colleagues in the United States, Canada, Europe, and Australia on projects dedicated to making TMS treatments more effective, and above all more accessible, for patients with depression and other psychiatric disorders.  The long-term objective of this work is to achieve large and measurable reductions in the worldwide prevalence of depression and mental illnesses, within our lifetimes, via a new generation of safe, scalable, and effective brain-based interventions.

December 6th, 2022 from  5:00 PM to  6:00 PM
United States
Phone: 845-392-3238
Event Fee(s)
Fee Level
Webinar Registration | Non-Member $50.00